Literature DB >> 20038476

Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation.

Deborah H Kwon1, Nicholas G Smedira, Maran Thamilarasan, Bruce W Lytle, Harry Lever, Milind Y Desai.   

Abstract

OBJECTIVE: In patients with hypertrophic cardiomyopathy with bifid hypermobile papillary muscles and a dynamic left ventricular outflow tract gradient, we performed surgical papillary muscle reorientation, fixing the mobile papillary muscle to the posterior left ventricle to reduce mobility. We report the outcomes of patients with hypertrophic cardiomyopathy undergoing surgical papillary muscle reorientation versus those of patients undergoing standard surgical procedures.
METHODS: We studied 204 consecutive patients with hypertrophic cardiomyopathy undergoing surgical intervention (after consensus decision) for symptomatic left ventricular outflow tract gradient. Preoperative and postoperative maximal (resting/provocable) left ventricular outflow tract gradients were recorded by using echocardiographic analysis.
RESULTS: The population was divided into 3 groups: (1) isolated myectomy (n = 143; age, 54 +/- 14 years; 48% men), (2) myectomy plus mitral valve repair/replacement (n = 39; age, 54 +/- 13 years; 54% men), and (3) papillary muscle reorientation with or without myectomy (n = 22; age, 50 +/- 14 years; 59% men). The mean preoperative (103 +/- 32, 103 +/- 32, and 114 +/- 36 mm Hg; P = .3) and predischarge (15 +/- 18, 14 +/- 14, and 16 +/- 21 mm Hg; P = .9) maximal left ventricular outflow tract gradients were similar. There were no deaths either in the hospital or at 30 days. At a median follow-up of 166 days (interquartile range, 74-343 days), 21 of 22 patients in group 3 were asymptomatic. One patient in group 3 had a symptomatic left ventricular outflow tract gradient (87 mm Hg) requiring mitral valve replacement.
CONCLUSIONS: In patients with hypertrophic cardiomyopathy with bifid hypermobile papillary muscles (even with a basal septal thickness <1.5 cm), papillary muscle reorientation reduces the symptomatic left ventricular outflow tract gradient. Long-term outcomes need to be ascertained. Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 20038476     DOI: 10.1016/j.jtcvs.2009.10.045

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  23 in total

1.  Left ventricular outflow tract obstruction with abnormal papillary muscles.

Authors:  Kotaro Oe; Tsutomu Araki; Miho Ohira; Tetsuo Konno; Masakazu Yamagishi
Journal:  J Cardiol Cases       Date:  2014-11-25

Review 2.  The effects of septal myectomy and alcohol septal ablation for hypertrophic cardiomyopathy on the cardiac conduction system.

Authors:  Patrick Fitzgerald; Fred Kusumoto
Journal:  J Interv Card Electrophysiol       Date:  2018-08-10       Impact factor: 1.900

3.  How to Treat Obstructions in Patients with Hypertrophic Cardiomyopathy.

Authors:  Josef Veselka
Journal:  Int J Angiol       Date:  2015-06

Review 4.  Complementary Role of Echocardiography and Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy.

Authors:  Waseem Hindieh; Raymond Chan; Harry Rakowski
Journal:  Curr Cardiol Rep       Date:  2017-09       Impact factor: 2.931

5.  Isolated septal myectomy for hypertrophic obstructive cardiomyopathy: an update on the Toronto General Hospital experience.

Authors:  Rachel D Vanderlaan; Anna Woo; Anthony Ralph-Edwards
Journal:  Ann Cardiothorac Surg       Date:  2017-07

6.  Cardiac magnetic resonance in hypertrophic cardiomyopathy.

Authors:  Milind Y Desai; Ashwat Dhillon; Andrew C Y To
Journal:  Curr Cardiol Rep       Date:  2011-02       Impact factor: 2.931

Review 7.  Evaluation of Hypertrophic Cardiomyopathy: Newer Echo and MRI Approaches.

Authors:  Manhal Habib; Sara Hoss; Harry Rakowski
Journal:  Curr Cardiol Rep       Date:  2019-06-26       Impact factor: 2.931

8.  Minimally invasive trans-mitral septal myectomy for diffuse-type hypertrophic obstructive cardiomyopathy.

Authors:  Taichi Sakaguchi; Toshinori Totsugawa; Kentaro Tamura; Arudo Hiraoka; Genta Chikazawa; Hidenori Yoshitaka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-03-16

9.  Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy.

Authors:  Constantinos O'Mahony; Saidi A Mohiddin; Charles Knight
Journal:  Interv Cardiol       Date:  2014-04

10.  A retrospective clinical study of transaortic extended septal myectomy for obstructive hypertrophic cardiomyopathy in China.

Authors:  Shuiyun Wang; Mingyao Luo; Hongtao Sun; Yunhu Song; Chaohua Yin; Liqing Wang; Rutai Hui; Shengshou Hu
Journal:  Eur J Cardiothorac Surg       Date:  2012-07-03       Impact factor: 4.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.